CA1250092A - Polypeptide diuretic/vasodilators - Google Patents
Polypeptide diuretic/vasodilatorsInfo
- Publication number
- CA1250092A CA1250092A CA000479612A CA479612A CA1250092A CA 1250092 A CA1250092 A CA 1250092A CA 000479612 A CA000479612 A CA 000479612A CA 479612 A CA479612 A CA 479612A CA 1250092 A CA1250092 A CA 1250092A
- Authority
- CA
- Canada
- Prior art keywords
- auriculin
- gly
- compounds
- arg
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 30
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 25
- 239000002934 diuretic Substances 0.000 title claims abstract description 23
- 230000001882 diuretic effect Effects 0.000 title claims abstract description 9
- 229940124549 vasodilator Drugs 0.000 title abstract description 4
- 239000003071 vasodilator agent Substances 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 38
- 230000001452 natriuretic effect Effects 0.000 claims description 19
- 230000002883 vasorelaxation effect Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 10
- 102000015427 Angiotensins Human genes 0.000 claims description 8
- 108010064733 Angiotensins Proteins 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 5
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- VQGWUEFARIAFPF-UHFFFAOYSA-N 5-hydroxy-7-(2-hydroxy-4-methoxyphenyl)-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one Chemical compound OC1=CC(OC)=CC=C1C(C(C1=C2O)=O)=COC1=C(CC=C(C)C)C1=C2C=CC(C)(C)O1 VQGWUEFARIAFPF-UHFFFAOYSA-N 0.000 abstract description 34
- 101800001288 Atrial natriuretic factor Proteins 0.000 abstract description 33
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 abstract description 32
- FQXZITIIHQHGBC-UHFFFAOYSA-N UNPD773 Natural products CC(C)=CCC1=CC(C(=O)OCC2C3CCCN3CC2)=CC(CC=C(C)C)=C1OC1OC(CO)C(O)C(O)C1O FQXZITIIHQHGBC-UHFFFAOYSA-N 0.000 abstract description 30
- 238000000034 method Methods 0.000 abstract description 13
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 abstract description 7
- 208000004880 Polyuria Diseases 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 6
- 206010047141 Vasodilatation Diseases 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000024883 vasodilation Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000001746 atrial effect Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000029142 excretion Effects 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 108090000783 Renin Proteins 0.000 description 6
- 102100028255 Renin Human genes 0.000 description 6
- 229960002478 aldosterone Drugs 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000004872 arterial blood pressure Effects 0.000 description 5
- 210000002565 arteriole Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010016807 Fluid retention Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- -1 cysteine Chemical class 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002497 edematous effect Effects 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000036454 renin-angiotensin system Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 101100066898 Mus musculus Flna gene Proteins 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000036581 peripheral resistance Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000010245 tubular reabsorption Effects 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WUFHQKHAKHCKJG-NNAOVHMHSA-N 91421-87-3 Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)=O)[C@@H](C)CC)[C@@H](C)CC)C1=CC=CC=C1 WUFHQKHAKHCKJG-NNAOVHMHSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002833 natriuretic agent Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- C07K14/582—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin at least 1 amino acid in D-form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Abstract NOVEL POLYPEPTIDE DIURETIC/VASODILATORS
Methods and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering auriculin or a synthetic analog of auriculin to said host.
Methods and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering auriculin or a synthetic analog of auriculin to said host.
Description
25009;~ (~
. .
, Description NOVEL POLYPEPTIDE DIURETIC/VASODILATORS
Technical Field The present invention relates generally to poly-peptides capable of regulating~ sodium excretion and blood pressure in mammals. More particularly, the present invention is directed to methods and compo-sitions analogous to polypeptides isolated from atrial tissue which are capable of inducing diuresis, natri-uresis and vasodilatation by the pharmaceutical admin-istration of effective amounts of selected polypep-tides.
Background Art Most multi-cellular organisms are organized into tissues and organs which perform specialiged functions.
Thus, a system has evolved to transport materials ~ between them. In higher animals, including mammals, ;~ this circulatory system is closed to improve the ; efficiency of transport. The flow of blood fluid through this closed cardiovascular~system requires that the fluid be maintained under pressure and the regula-tion of the systemic arterial blood pressure requires a complex interactlon of numerous factors including, ~- e.g., fluid volume and vascular elasticity and caliber.
The maintenance of normal extracellular fluid volume depends pr;imarily on the excretion of sodium ~ (natriuresis) and water (diuresis) by the kidneys.
`~ This is determined by (1) the rate at which plasma is filtered~at the glomerulus (glomerular filtration rate, or GFR) and (2) the degree to which~sodium is actively reabsorbed along the renal tubule (with water following passively). The latter process is in part regulated by the adrenal steroid hormone aldosterone. It has been~
~ .
' .~ . .
. , :
~5()~9;~
..
long believed that, in addition to GFR and aldosterone, there must be a "third factor" which also regulates sodium reabsorption. It is now apparent that many of the phenomena which required the postulation of a "third factor" can be explained by the effects of physical forces (e.g. blood pressure, red bloo~ cell concentation and plasma viscosity) on sodium reabsorp-tion. Nonetheless, the search continues for a "natri-uretic hormone" which might directly inhibit tubular reabsorption.
There are several candidates for such a hormone, among which are included the natriuretic factor(s) recently isolated from atrial muscle cells. A natri-uretic effect has been demonstrated by crude extracts of rat atrial tissue but not ventricular tissue.
De Bold, A.J. et al., Life Sciences, 28:89-34 (1981~, Garcia, R., Experientia, 38:1071-73 (1982), Currie, - M.G. et al., Science 221:71-73 (1983). Various pep-tides with diuretic and natriuretic properties have been isolated from atrial tissue and sequenced. Flynn, T.G. et al., Biochem. Biophys. Res. Commun. 117:859-865 ~1983), Currie, M.G. et al., Science 223:67-69 (1984), Kangawa, K. et al., Biochem. Biophys. ~es. Commun.
; 118:131-139 (1984). The existence of these atrial natriuretic factors strengthens the long-held suspicion that the heart, aside from its obvious influence on renal perfusion, may play an important role in regulat-ing renal sodium and water excretion. Stretching of the atria is known to induce diuresis and natriuresis, and this is possibly mediated by increased release of~
these factors.
A number of clinically important disease states are characterized by abnormal fluid volume retention.
Congestive heart failurej cirrhosis of the li~er and the nephrotic syndrome each lead to excessive ~luid ~ accumulation on the venous side o~ the circula~ion, the : -' : : ~
: , ., ,.~ ~, .... .. . .
' ``~ :
`
:
,(-'. ~,'`.
Z50~9;~
presumed common mechanism being under-perf~sion of the kidneys leading to a fall in GFR. In addition the reduced renal perfusion stimulates excessive secretion of renin, a proteolytic enzyme whose action in the circulation leads to the formation of angiotensin.
Angiotensin is a powerful constrictor of arterioles (which helps to maintain arterial pressure) and also stimulates release of the sodium-retaining hormone aldosterone by the adrenal gland (which further worsens fluid retention). These mechanisms do not, however, fully account for the fluid retention-of the so-called "edematous states", and additional factors are likely to be involved. One important possibility is that a relative or absolute deficiency of atrial natriuretic factor, caused either by chronic over-stretching of the atrium (e.g., heart failure) or by inadequate stimula-tion of the atrium (e~g., cirrhosis and nèphrotic syndrome), might contribute to the fluid retention.
An increase in extracellular fluid volume is also thought to contribute to the development of hy~erten-sion in many instances. Hypertension, or chronically èlevated blood pressure, is one of the major causes of illness and death worldwide. It is estimated that more than 20 million Americans suffer from this disease whose complications include heart failure, heart attack, stroke and kidney failure. The major observed ; hemodynamic abnormality in chronic hypertension is increased resistance to the flow of blood through the ~ arterioles. The mechanisms which lead to this in-~`~ 30 creased "peripheral resistance" are, however, incom-pletely understood. In some cases inappropriate activity of the renin-angiotensin system or sympathetic nervous system may lead to excessive constriction of the arterioles; by "inappropriate" it is meant that the i 35 unknown signal(s) leading to this activity are not based upon a physiological need of the organism and ~:
.
- .
(~ (~''"
~ ` 12S~¢~9~ ~`
thus lead to elevated blood pressure (whereas, in the example cited earlier, the increased renin secretion in the edematous states is a response to reduced arterial pressure and thus helps to restore or maintain normal pressure). In a substantial fraction of hypertensives however, inappropriate sodium and volume retention by the kidney is felt to either initiate or contribute to the elevated blood pressure. The responsible defect in kidney function and the mechanism whereby fluid reten-tion leads to increased peripheral resistance are both - unknown. It is certainly possible that deficiency of a natriuretic hormone could be responsible for these observations, particularly if the same substance also normally exerted a relaxant effect on arterioles.
Diuretic therapy is currently a mainstay in the treatment of hypertension, renal failure and the various edematous states (heart failure, etc.). Cur-rently available pharmacological preparations have, however, several important limitations and undesirable effects. While their use may be directed at a specific abnormality (i.e. volume e~pansion), their multiple actions are undoubtedly not physiological, leading for instance to potassium depletion, increased retention of uric acid and abnormal glucose and lipid metabolism.
In addition, all known diuretics profoundly stimulate the renin-angiotensin-aldosterone system, which coun-teracts their volume-depleting and blood pressure-lowering effects and leads to other unwanted effects.
It would be desirable to provide a pharmacologically effective compound which can regulate blood pressure by providing a complete but controlled range of physio-logical responses.
Accordingly, it is the principal object of the present invention to provide methods and compounds for influencing fluid volume and blood pressure homeostasis ~ in mammals.
:
- .
.
` '' ~" ~ZS~ g;;;~ (~
It is another object o~ the present invention to provide methods and compounds which mimic the physio-logical regulation of fluid volume and blood pressure in mammals.
Disclosure of the Invention The obtainment of these and other objects of the invention is provided by methods and compositions of the present invention which include auriculin substan-tially free of unrelated atrial tissue or products.
Compositions of the present invention useful as natriuretics, diuretics, vasodilators and modulators of the renin-angiotensin-aldosterone system include polypeptide compounds identified by the formula:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH
Also provided are methods for using compounds of the present invention as diagnostic and therapeutic agents.
Brief Description of the Drawings~
Figure tA-D are graphic representations of the purification of compounds of the present invention from atrial tissue, in which: ~
Figure lA displays the results of G-50 gel filtra-tion of crude extract;
Figure 1B displays the result~ of HPLC (C18 column) purification of refined extract;
Figure 1C displays the re-chromatography of the product of Figure lB; and Figure lD displays the results of HPLC (CN coIumn) purification of the purified active fractions of Figure lC;
:; , :
::
:,; ~ ,, ~ :: ' :
~ ~ .
SIDO9;;~
1.
Figure 2 is a comparison of the vasorelaxant activity of purified and synthetic compounds of the present invention; and Figure 3 is a comparison of the vascular action of synthetic compounds of the present invention in the absence (A) or presence (B) of angiotensinogen (the precursor cleaved by renin to produce angiotensin).
Best Mode for Practicing the Invention In accordance with the present invention methods - 10 and compositions are provided for the-regulation of fluid volume and blood pressure in mammals, in which one aspect of the invention provides auriculin substan-tially free of unrelated atrial tissue or products.
Another aspect of the invention provides polypep-tide compounds comprising the formula:H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH
The nomenclature used to describe polypeptides of the present invention follows the conventional practice of using the first three letters oE the trivial name of ; the amino acid and wherein the L form of any amino acid having an optical isomer is intended unless otherwise expressly indicated.
Compounds within the scope of the present inven-tion can also be obtained by modifying the above recited formula in numerous ways while preserving the activity of the polypeptides thus obtained. For example, while the amino acids of these polypeptide compounds are normally in the natural L form, one or -~ more, usually two or less and preferably one amino acid may be replaced with the optical isomer D form. Amino acid residues contained within the polypeptide com-pounds can also be modified by acetylation or substi-tuted with other chemical groups which can, for :' :
:
':'"`''' ~ ' ' .
,~
~25[)Q9~ ~
example, change the solubility of the compounds without effecting their activity.
In addition, one or more amino acid residues can be replaced by functionally equivalent residues; for example basic amino acids can be replaced with other basic amino acids and acidic amino acids can be re-placed with other acidic amino acids. However, the replacement of hydrophobic amino acids, particularly cysteine, are considered less desirable due to the likelihood of interfering with the presumptive disul-fide bridge between residues 4 and 20.
Further modifications are possible by extending or decreasing, preferably extending, the compounds' amino acid sequence by the addition of amino acids or oligo-peptides on the N-terminal or preferably C-terminal end of the sequence disclosed above. Particularly, X can be amide or an amino acid or oligopeptide of not more than about 8, usually 5, and desirably 4 amino acids which do not adversely effect natriuretic, diuretic and vasorelaxant activity of the subject~compounds. Fur-thermore, compounds of the present invention can be bonded to ox conjugated with compounds having the same range of activities to obtain the benefits of the present invention.
Preferred compounds of the present invention have been isolated from atrial tissue of rats, substantially free of unrelated atrial tissue or products. Gener-ally, acetic acid extracts of atrial tissue are sub-jected to gel filtrationr and reversed phase high performance liquid chromatography (using C18 and CN
columns), while assaying for the natriuretic and vasorelaxant activity of the fractions.
Compounds within the scope~of the present inven-tion can be isolated and purified from biological tissue sources, notably mammalian atrial tissue sources, or can be synthesized chemlcally by means , :
`
; ` ~ " , ' - ................................................. , , ~ .
lZS~C~9;~
.
well-known in the art such as, e.g., solid phase synthesis. The synthesis is commenced rom the C-terminal end of the peptide using an alpha-amino protected amino acid. t-Butyloxycarbonyl (~oc) protec-tive groups can be used for all amino groups eventhough other protective groups are suitable. For example, Boc-~rg-OH or Boc-Tyr-OH ~i.e., the C-terminal amino acids) can be esterified to brominated poly-styrene resin supports. The polystyrene resin support is preferably a copolymer of styrene with about 0.5 to
. .
, Description NOVEL POLYPEPTIDE DIURETIC/VASODILATORS
Technical Field The present invention relates generally to poly-peptides capable of regulating~ sodium excretion and blood pressure in mammals. More particularly, the present invention is directed to methods and compo-sitions analogous to polypeptides isolated from atrial tissue which are capable of inducing diuresis, natri-uresis and vasodilatation by the pharmaceutical admin-istration of effective amounts of selected polypep-tides.
Background Art Most multi-cellular organisms are organized into tissues and organs which perform specialiged functions.
Thus, a system has evolved to transport materials ~ between them. In higher animals, including mammals, ;~ this circulatory system is closed to improve the ; efficiency of transport. The flow of blood fluid through this closed cardiovascular~system requires that the fluid be maintained under pressure and the regula-tion of the systemic arterial blood pressure requires a complex interactlon of numerous factors including, ~- e.g., fluid volume and vascular elasticity and caliber.
The maintenance of normal extracellular fluid volume depends pr;imarily on the excretion of sodium ~ (natriuresis) and water (diuresis) by the kidneys.
`~ This is determined by (1) the rate at which plasma is filtered~at the glomerulus (glomerular filtration rate, or GFR) and (2) the degree to which~sodium is actively reabsorbed along the renal tubule (with water following passively). The latter process is in part regulated by the adrenal steroid hormone aldosterone. It has been~
~ .
' .~ . .
. , :
~5()~9;~
..
long believed that, in addition to GFR and aldosterone, there must be a "third factor" which also regulates sodium reabsorption. It is now apparent that many of the phenomena which required the postulation of a "third factor" can be explained by the effects of physical forces (e.g. blood pressure, red bloo~ cell concentation and plasma viscosity) on sodium reabsorp-tion. Nonetheless, the search continues for a "natri-uretic hormone" which might directly inhibit tubular reabsorption.
There are several candidates for such a hormone, among which are included the natriuretic factor(s) recently isolated from atrial muscle cells. A natri-uretic effect has been demonstrated by crude extracts of rat atrial tissue but not ventricular tissue.
De Bold, A.J. et al., Life Sciences, 28:89-34 (1981~, Garcia, R., Experientia, 38:1071-73 (1982), Currie, - M.G. et al., Science 221:71-73 (1983). Various pep-tides with diuretic and natriuretic properties have been isolated from atrial tissue and sequenced. Flynn, T.G. et al., Biochem. Biophys. Res. Commun. 117:859-865 ~1983), Currie, M.G. et al., Science 223:67-69 (1984), Kangawa, K. et al., Biochem. Biophys. ~es. Commun.
; 118:131-139 (1984). The existence of these atrial natriuretic factors strengthens the long-held suspicion that the heart, aside from its obvious influence on renal perfusion, may play an important role in regulat-ing renal sodium and water excretion. Stretching of the atria is known to induce diuresis and natriuresis, and this is possibly mediated by increased release of~
these factors.
A number of clinically important disease states are characterized by abnormal fluid volume retention.
Congestive heart failurej cirrhosis of the li~er and the nephrotic syndrome each lead to excessive ~luid ~ accumulation on the venous side o~ the circula~ion, the : -' : : ~
: , ., ,.~ ~, .... .. . .
' ``~ :
`
:
,(-'. ~,'`.
Z50~9;~
presumed common mechanism being under-perf~sion of the kidneys leading to a fall in GFR. In addition the reduced renal perfusion stimulates excessive secretion of renin, a proteolytic enzyme whose action in the circulation leads to the formation of angiotensin.
Angiotensin is a powerful constrictor of arterioles (which helps to maintain arterial pressure) and also stimulates release of the sodium-retaining hormone aldosterone by the adrenal gland (which further worsens fluid retention). These mechanisms do not, however, fully account for the fluid retention-of the so-called "edematous states", and additional factors are likely to be involved. One important possibility is that a relative or absolute deficiency of atrial natriuretic factor, caused either by chronic over-stretching of the atrium (e.g., heart failure) or by inadequate stimula-tion of the atrium (e~g., cirrhosis and nèphrotic syndrome), might contribute to the fluid retention.
An increase in extracellular fluid volume is also thought to contribute to the development of hy~erten-sion in many instances. Hypertension, or chronically èlevated blood pressure, is one of the major causes of illness and death worldwide. It is estimated that more than 20 million Americans suffer from this disease whose complications include heart failure, heart attack, stroke and kidney failure. The major observed ; hemodynamic abnormality in chronic hypertension is increased resistance to the flow of blood through the ~ arterioles. The mechanisms which lead to this in-~`~ 30 creased "peripheral resistance" are, however, incom-pletely understood. In some cases inappropriate activity of the renin-angiotensin system or sympathetic nervous system may lead to excessive constriction of the arterioles; by "inappropriate" it is meant that the i 35 unknown signal(s) leading to this activity are not based upon a physiological need of the organism and ~:
.
- .
(~ (~''"
~ ` 12S~¢~9~ ~`
thus lead to elevated blood pressure (whereas, in the example cited earlier, the increased renin secretion in the edematous states is a response to reduced arterial pressure and thus helps to restore or maintain normal pressure). In a substantial fraction of hypertensives however, inappropriate sodium and volume retention by the kidney is felt to either initiate or contribute to the elevated blood pressure. The responsible defect in kidney function and the mechanism whereby fluid reten-tion leads to increased peripheral resistance are both - unknown. It is certainly possible that deficiency of a natriuretic hormone could be responsible for these observations, particularly if the same substance also normally exerted a relaxant effect on arterioles.
Diuretic therapy is currently a mainstay in the treatment of hypertension, renal failure and the various edematous states (heart failure, etc.). Cur-rently available pharmacological preparations have, however, several important limitations and undesirable effects. While their use may be directed at a specific abnormality (i.e. volume e~pansion), their multiple actions are undoubtedly not physiological, leading for instance to potassium depletion, increased retention of uric acid and abnormal glucose and lipid metabolism.
In addition, all known diuretics profoundly stimulate the renin-angiotensin-aldosterone system, which coun-teracts their volume-depleting and blood pressure-lowering effects and leads to other unwanted effects.
It would be desirable to provide a pharmacologically effective compound which can regulate blood pressure by providing a complete but controlled range of physio-logical responses.
Accordingly, it is the principal object of the present invention to provide methods and compounds for influencing fluid volume and blood pressure homeostasis ~ in mammals.
:
- .
.
` '' ~" ~ZS~ g;;;~ (~
It is another object o~ the present invention to provide methods and compounds which mimic the physio-logical regulation of fluid volume and blood pressure in mammals.
Disclosure of the Invention The obtainment of these and other objects of the invention is provided by methods and compositions of the present invention which include auriculin substan-tially free of unrelated atrial tissue or products.
Compositions of the present invention useful as natriuretics, diuretics, vasodilators and modulators of the renin-angiotensin-aldosterone system include polypeptide compounds identified by the formula:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH
Also provided are methods for using compounds of the present invention as diagnostic and therapeutic agents.
Brief Description of the Drawings~
Figure tA-D are graphic representations of the purification of compounds of the present invention from atrial tissue, in which: ~
Figure lA displays the results of G-50 gel filtra-tion of crude extract;
Figure 1B displays the result~ of HPLC (C18 column) purification of refined extract;
Figure 1C displays the re-chromatography of the product of Figure lB; and Figure lD displays the results of HPLC (CN coIumn) purification of the purified active fractions of Figure lC;
:; , :
::
:,; ~ ,, ~ :: ' :
~ ~ .
SIDO9;;~
1.
Figure 2 is a comparison of the vasorelaxant activity of purified and synthetic compounds of the present invention; and Figure 3 is a comparison of the vascular action of synthetic compounds of the present invention in the absence (A) or presence (B) of angiotensinogen (the precursor cleaved by renin to produce angiotensin).
Best Mode for Practicing the Invention In accordance with the present invention methods - 10 and compositions are provided for the-regulation of fluid volume and blood pressure in mammals, in which one aspect of the invention provides auriculin substan-tially free of unrelated atrial tissue or products.
Another aspect of the invention provides polypep-tide compounds comprising the formula:H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH
The nomenclature used to describe polypeptides of the present invention follows the conventional practice of using the first three letters oE the trivial name of ; the amino acid and wherein the L form of any amino acid having an optical isomer is intended unless otherwise expressly indicated.
Compounds within the scope of the present inven-tion can also be obtained by modifying the above recited formula in numerous ways while preserving the activity of the polypeptides thus obtained. For example, while the amino acids of these polypeptide compounds are normally in the natural L form, one or -~ more, usually two or less and preferably one amino acid may be replaced with the optical isomer D form. Amino acid residues contained within the polypeptide com-pounds can also be modified by acetylation or substi-tuted with other chemical groups which can, for :' :
:
':'"`''' ~ ' ' .
,~
~25[)Q9~ ~
example, change the solubility of the compounds without effecting their activity.
In addition, one or more amino acid residues can be replaced by functionally equivalent residues; for example basic amino acids can be replaced with other basic amino acids and acidic amino acids can be re-placed with other acidic amino acids. However, the replacement of hydrophobic amino acids, particularly cysteine, are considered less desirable due to the likelihood of interfering with the presumptive disul-fide bridge between residues 4 and 20.
Further modifications are possible by extending or decreasing, preferably extending, the compounds' amino acid sequence by the addition of amino acids or oligo-peptides on the N-terminal or preferably C-terminal end of the sequence disclosed above. Particularly, X can be amide or an amino acid or oligopeptide of not more than about 8, usually 5, and desirably 4 amino acids which do not adversely effect natriuretic, diuretic and vasorelaxant activity of the subject~compounds. Fur-thermore, compounds of the present invention can be bonded to ox conjugated with compounds having the same range of activities to obtain the benefits of the present invention.
Preferred compounds of the present invention have been isolated from atrial tissue of rats, substantially free of unrelated atrial tissue or products. Gener-ally, acetic acid extracts of atrial tissue are sub-jected to gel filtrationr and reversed phase high performance liquid chromatography (using C18 and CN
columns), while assaying for the natriuretic and vasorelaxant activity of the fractions.
Compounds within the scope~of the present inven-tion can be isolated and purified from biological tissue sources, notably mammalian atrial tissue sources, or can be synthesized chemlcally by means , :
`
; ` ~ " , ' - ................................................. , , ~ .
lZS~C~9;~
.
well-known in the art such as, e.g., solid phase synthesis. The synthesis is commenced rom the C-terminal end of the peptide using an alpha-amino protected amino acid. t-Butyloxycarbonyl (~oc) protec-tive groups can be used for all amino groups eventhough other protective groups are suitable. For example, Boc-~rg-OH or Boc-Tyr-OH ~i.e., the C-terminal amino acids) can be esterified to brominated poly-styrene resin supports. The polystyrene resin support is preferably a copolymer of styrene with about 0.5 to
2~ divinyl benzene as a cross-linking-agent which causes the polystyrene polymer to be completely insolu-ble in certain organic solvents. See Stewart et al., Solid-Phase Peptide Synthesis, W. H. Freeman Co., San Francisco ~1969) and Merrifield, J., Am. Chem. Soc.
85:2149-2154 (1963).
Conveniently, polypeptides may be synthesized automatically employing, for example, a Biosearch SAM
II automatic peptide synthesizer (Biosearch, Inc. San Rafael, CaliEornia) as described in the instruction manual~
Compounds of the present invention are shown to have natriuretic and diuretic activity in the intact mammal and in the kid~ey isolated from a mammal.
Furthermore, compounds of the present invention includ-ing synthetic compounds, possess vasorelaxant activity, which has been shown ~o be enhanced by slow o~idation, which indicates the li~elihood of a disulfide Cys-Cys bridge between residues 4 and 20 in the general formula ; 30 indicated previously.
Compounds oE the present invention which are shown to have the above recited physiological efects can find use in numerous therapeutical applications such as, e.g., inducing ~atriuresis, diuresis, and vasodila-tation. Thus these compounds can find use as thera-peutic agents in the treatment of various edematous * trade mark . ~
, :
:` .
~ ~s`;v~
~S~)Q9~
g states such as, for example, congestive heart failure, nephrotic syndrome and hepatic cirrhosis, in addition to hypertension and renal failure due to ineffective renal perfusion or reduced glomerular filtration rate.
These compounds can be administered to mammals for veterinary use such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents, that is in a physiologically acceptable carrier. In general the dosage will range from about OoOl to 100 ~g/kg, more usually 0.1 to 10 ~g/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits have been obtained.
These compounds can be administered neat, as mixtures ~ith other physiologically acceptable active or inactive materials, or with physiologically suitable carriers such as, for example, water or normal saline.
The compounds can be administered orally or paren-; terally, for example, by injection. Injection can be subcutaneous, intravenous, or by intramuscular injec-; tion.
These compounds are desirably administered in - 25 pharmaceutically effective amounts and often as pharma-~- cologically acceptable salts such as acid addition salts. Such salts can include, e.g., hydrochloride, hydrobromide, phosphate, sulphate, acetate, benzoate, malate, among others.
Compounds of the present invention can also be used for preparing antisera for use in immunoassays employing labelled reagents, usually antibodies.
Conveniently, the polypeptides can be conjugated to an antigen by means of dialdehydes, particularly from 4 to 6 carbon atoms and aliphatic, or carbodiimide. Thesè
: -. , ~s~og~ - ~
compounds and immunologic reagents may be labelled with a variety of labels such as chromophores, fluorophores such as, e.g., fluorescein or rhodamine, radioisotopes such as 125I, 35S, 14C, or 3H, or magnetized particles, by means well known in the art.
These labeled compounds and reagents, or labeled reagents capable of recognizing and specifically binding to them, can find use as, e.g., diagnostic reagents. Samples derived from biological specimens can be assayed for the presence or amount of substances having a common antigenic determinant with compounds of the present invention. In addition, monoclonal anti-bodies can be prepared by methods known in the art, which antibodies can find therapeutic use, e.g., to neutralize overproduction of immunologically related compounds ln vivo.
The following examples are provided by way of illustration, rather than implying any limitation of the subject invention.
EXPERIMENTAL
Isolation and Purification The following compound was isolated from atrial tissue as follows:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-O~
These compounds and their synthetic polypeptide analogs are referred to as auriculin.
The polypeptide was purified from an acetic acid extract of atria from 1400 male Wistar rats by first homogenizing~the ~tissue in 8 volumes of 1 N acetic acid containing 1 mM phenylmethylsulfonyl fluoride (PMSF
~; Sigma Chemical Co., St. Louis, Mo.), 3 mM ethyl-enediaminetetraacetic acid (EDTA) and 5 ~M pepstatin A
(pepsin and renin inhibitor, Sigma Chemical Co., St.
::
.
~ ' ~
:~ :
:: :
- ~2S~Q9~
--1 1~
Louis, MO). This homogenate was centrifuged at 10,800 x g for 30 minutes and the pellet was rehomogenized in 4 volumes of the original buffer. The supernate from the second extract was pooled and the pooled super-natants were neutralized with ammonium hydroxide. Theneutralized supernatants were then centrifuged at 10,000 x g for 20 minutes and lyophilized.
The lyophilized extract was subjected to gel filtration on a 2.5 X 45 cm column of Sephadex~ G-50 (fine, Pharmacia Fine Chemicals, Piscataway, NJ) which had been equilibrated with 1 N acetic-acid. The lyophilized extract was reconstituted with 6 ml buffer, centrifuged and applied to the column and then eluted at a flow rate of 0.63 ml/minute. Aliquots from each fraction were dried (Savant Speed-Vac*concentrator), reconstituted in phosphate buffered saline (PBS) and ~- assayed for natriuretic activity in intact rat and for ; vasorelaxant activity using rabbit aortic rings.
~~The results of this chromatographic step were as shown in Figure 1~, and the regions contained in horizontal bracket were lyophilized, reconstituted with 0.1% aqueous trifluoroacetic acid (TFA), pooled and centrifuged.
The pooled material was adjusted to 15% aceto-nitrile (CH3CN) and was ap~lied to a 0.39 X 30.0 centi-meter ~-Bondapak*C18 column (Waters,~Inc., Milford, MA). The material was applied using a ~aters U6K
injector and solvent delivery system (Waters, Inc., Milford, MA). Bound material was eluted at 0.1 ml/min.
with a linear gradient of solvents A (0.1~ TEA): B
(CH3CN) from 85:15 to 45:55 over 40 minutes.
Aliquots of the fractions were assayed for natri-uresis in the isolated kidney and vasorelaxant activity - as described subsequently. A broad region of coinci-dent natriuretic and vasorelaxant activi~y was eluted ` and these fractions were pooled and dried.
* trade mark b ~
~zs~9~
-12~
The material obtained and dried was reconstituted in A:B, 78:22, and rechromatographed (in 12 separate applications) at 1.0 ml/min. using a gradient of 22 tQ
34% B over 48 minutes. Aliquots of the fractions were tested for natriuretic and vasorelaxant activities as described above. The results were as displayed in Figure 1B. Fractions from the three active peaks were pooled and dried overnight.
The combined fractions from the second peak (indicated by bracketed area in Figure lB) was reconstituted in A:B, 77:23, applied to a C18 column and eluted at 0.4 ml/min. using a gradient of 23 to ~9%
B over 90 minutes. The results of this rechroma-tography were as shown in Figure 1C, where the brack-eted area indicates fractions with vasorelaxant activ-ity. Active fractions from 6 applications were pooled.
The material thus obtained was applied to a 0.39 X
30 cm ~-Bondapak CN column (Waters, Inc., Milford, MA).
The solvent system used was A (0.1% TFA in water) and B
(0.055% TFA in CH3CN). The sample was reconstituted in A:B, 90:10, and chromatographed in three separate applications at 0.6 ml/min. using a gradient of 10 to 30~ B over 60 minutes. Vasorelaxant activity was determined by the reduction in tension produced in histamine-contracted aortic rings as described subse-quently.
The active peak, indicated by the bracket in Figure 1D, was dried and sequenced. The sequence was determined from one nanomole of protein using the Applied Biosystems 470A gas-phase sequencer (Applied Biosystems Inc., Foster City, CA) in accordance with the instructions of the manufacturer. PTH amino acids were identified with a Beckman 334 T HPLC, using a 0.46 X 25 cm IBM CN-column. The gradient applied was as : :
indicated in Hunkapiller, N. W. and L. E. Hood, Methods :~ in Enzymolog~f, 91:486-492 (Academic Press, New York)~
~:
~;
:`` ::
lZS~3Q9~
(1983), with the following modiEications:the binary gradient system of Hunkapiller and Hood has been replaced by a ternary gradient system in which acetonitrile and methanol are pumped by separate pumps and the ratio of the two varied with time over the course of the gradient, with appropriate modification of the gradient program the Permaphase ETH~ guard column, specified by Hunkapiller and Hood, has been replaced with a 5 X 0.46 centimeter IBM CN analytical "mini-column"; and the analytical column is heated to - 28C whereas Hunkapillar and Hood specify 32C.
Because of the methods used to assay the products of the purification procedure, natriuretic and vaso-relaxant activity is an inherent property of the isolated and purified material.
'~' Chemical S~nthesis Compounds of the present invention having the formula:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-OH
were synthesized by solid-phase techniques. Synthesis was performed on a Biosearch SAM II automated peptide synthesi~er using t-BOC amino acids in accordance with the instructions of the manufacturer.
Following re?etitive deblocking cycles with TFA, i subse~uent couplings of amino acids were achieved with a water-soluble carbodiimide. Synthetic peptide was ~ removed from the polystyrene resins with liquid HF, `~ then was reduced, puri~ied and slowly reoxidized in accordance with the protocol of Rivier, J. E. F., J.
Amer. Chem. Soc., 96:2986-2992 (1974).
The polypeptide material was dissolved in 1 N
acetic acid containing 10 mM ~-mercaptoethanol and applied to a 2 X 96 cm column of Sephadex~ G-25 ~ * trade mark :, .~ .
. :
- :
( ~ ~250(~9~ ~
- (Pharmacia Fine Chemicals) equilabrated with the same buffer. The flow rate used was 0.335 ml/min. The major peak of UV (250 nm) absorbing material was lyophilized, resuspended in 0.05 M ammonium acetate, pH
7.2, to a final concentration of 50 ~g/ml. This material was allowed to reoxidize by exposure to air at 4DC in the dark for 60 hours and then lyophilized.
This polypeptide material was compared to par-tially-purified (Figure 1A) and purified (Figure 1D) auriculin for its ability to relax histamine-contracted aortic rings. Aortic rings were suspended in lO ml .
aerated Kreb's buffer under 1.5 grams passive tension.
The rings were precontracted with 6 X 10 M norepine-phrine, washed and allowed to return to baseline tension. A sustained contraction was induced with 5 ~M
histamine and increasing amounts of purified or synthe-tic peptide were added in cumulative fashion. The change in tension is related to the cumulative amount of protein added, as shown in Figure 2, wherein the open triangles represent polypeptide purified by gel filtration only, closed triangles represent completely purified polypeptide, open circles represent synthetic peptide before oxidation an8 closed circles represent synthetic polypeptide after oxidation.
Biologic Activity The biologic;activities of auriculin and its chemically synthesized analog were determined and compared using intact rats, isolated rat kidneys, intact dogs and isolated rabbit thoracic aortic rings.
The synthetic auriculin analog was compared to partially purified (gel filtration step) and purified (HPLC) auriculin for its ability to relax histamine-contracted aortic rings. Rings were suspended in 10 ml aerated Kreb's buffer under 1.5 g passive tension. ~
:' :
: ~
,, ~ -:-- , ~-; : ' , ' ' ~:
--:~25~()9;~
Rings were precontracted with 6 X 10 M norepine-phrine, washed and allowed to return to baseline tension, as described (Kleinert, H. D. (1984), supra).
A sustained contraction was induced with 5 uM histamine and then increasing amounts of purified auriculin or synthetic polypeptide were then added in cumulative fashion. The change in tension was shown to be related to the cumulative amount of protein added, as seen in Figure 2.
As alternatives, angiotensin, norepinephrine and potassium-induced depolarization were-used instead of histamine. Purified and synthetic auriculin demon-strated similar vasorelaxant effects.
The synthetic polypeptide auriculin analog was also found to be natriuretic in the intact rat. Syn-thetic peptide was administered as a bolus injection to Inactin anesthetized rats (100 mg/kg, average weight 399 g) which were maintained on a constant infusion of normal saline at 2.2 ml/hr. The results were as shown in Table I, wherein the change in each parameter was assessed by the difference between the averaqe of three control periods (10 mins. each) and the ~irst experi-mental period (maximum response). Data are expressed as mean + SE.
'~ ~ - ; :~
:
:: : : ~ '~ ' .
( ' (~',,, ~l2SVO9~
Table I
Natriuretic Effect of Synthetic Auriculin in Intact Rats Dose V UNaV UKV
5(~g/kg) (~l/min? (~Eq/min)(~Eq/min) 1.2 (n=4)25.5 + 9.7 2.5 + 1.11.6 + 0.2 2.6 ~n=4)41.3 + 19.5 6.7 + 4.14.4 + 1.4 5.0 (n=4)52.8 + 6.5 9.1 + 1.03,7 + 0.5 7.2 (n=3)112.0 + 12.818.3 + 0.53.1 + 0.8 . _ _ .. _ _ ... .. .
- 10 V, urine flow rate; UNaV, urinary so~ium excretion rate; UI~V, urinary potassiwn excretion rate. Control values for the 15 animals were: V, 10.3 + 2.9 ~l/min;
UNaV, 0.93 + 0.5 ~Eq/min; and UKV, 1.6 ~ 0.4 ~Eq/min.
The natriuretic activity of the synthetic polypep-tide auriculin analog was also measured in isolated rat ~; kidney. Functioning isolated rat kidneys were perfused in a closed-circuit system, as described in Camargo, M.J.F. et al. Am.J.Physiol., In Press. (19843. After control clearance periods, 150 ng of syntheti~ peptide was added to the perfusate. The ef~ects on each parameter were noted immediately and reached a maximum during the fourth 10 minute clearance period. These peak vaIues are expressed in,Table II as the experi-mental data. ~
.: :
;
: ' :
..
: ~ -~ZSOO9;~
Table II
Effects of Synthetic Auriculin on Renal Function in the Isolated Perfused Rat Kidney Control Experimental GFR (ml/min) 0.43 + 0.05 0.63 + 0.03*
FF 0.014 + 0.002 0.021 + 0.001*
RVR (mmHg/ml min) 2.9 + 0.1 3.9 + 0O3*
V (~l/min) 19.8 ~ 4.8 97.6 + 19.4*
FLNa (~Eq/min) 60.2 + 7.9 90.1 + 5.2*
TNa (~Eq/min) 60.0 + 7.6 84.2 + 4.8*
UNaV (~Eq/min) 0.66 + 0.35 6.01 + 1.99*
Na ( ) 0~97 + 0.38 6.6 ~ 2.0*
UKV (~Eq/min) 0.44 + 0.19 1.46 ~ 0.16*
FEK (~) 19.8 + 5.3 52.1 + 6.2*
_ GFR, glomerular filtration rate; FF, filtration frac-tion; RVR, renal vascular resistance; V, urine flow rate; FLNa, filtered load of sodium; TNa, tubular reabsorption of sodium; UNaV, urinary sodium excretion rate; FEN ~ fractional sodium excretion; UKV, urinary potassium excretion rate; FEK, fractional potassium excretion~ Results are the mean + SE of 4 kidneys.
*P 0.05 compared to control (Student's t test).
In these results it can be seen that isolated kidneys perfused in the absence of vasoconstrictors, the synthetic poIypeptide increased renal vascular resistance (see also Figure 3A), filtration fraction and glomerular filtration rate. In contrast, in isolated kidney pre-contracted with endogenously generated angiotensin, the synthetic peptide decreased vascular resistance (see Fiqure 3B). These effects with the synthetic peptide show that auriculin can have both renal vasoconstrictive and vasorelaxant activity depending on the absence or presence of endogenous vasoconstrictors. The natriuresis observed in the ~,.`,,, - :
.
(~ ,? (', ~2SOQ9;~
isolated kidney can result from a renal vasocon-strictive effect preferentially expressed in the efferent arteriole.
Renal and hemodynamic effects have also been measured in anesthetized dogs receiving a constant infusion of the synthetic peptide (1 ~g/kg bolus, followed by 0.1 ~g/kg/min for 1 hour). Immediate effects were noted on blood pressure, GFR and urine flow rate and electrolyte excretion which were sus-tained throughout the infusion. The "experimental"data presented for these parameters in Table III are the average values obtained during the infusion. Mean arterial pressure (MAP) fell consistently by l0-15~
while GFR rose by 25-35%, in association with a sus-tained diuresis and natriuresis (Table III). All theseparameters returned to control (i.e. pre-infusion) levels during the recovery period (i.e. following termination of the infusion).
::: :
:: :
: ~ ' ' .
J~2S(~9~
--, g Table III
-Hemodynamic, Renal and Metabolic Effects Of Synthetic Auriculin in Anesthetized Dogs Control Experimental_ Recovery MAP (mm Hg) 134 + 5 122 ~ 4* 136 + 4 GFR (ml/min) 25.5 + 2.7 32.3 + 4.1* 25.4 + 3.3 V (ml/min) 0.21 + 0.03 1.06 + 0.14* 0.37 + 0.05 2 0.9 + 0.2 3.4 + 0.3* 1.5 + 0.2 UNaV ( Eq/min) 38 + 6 187 + 35* 68 + 14 FENa (~) 1.1 + 0.2 4.1 + 0.5* 1.9 0.4 UKV ( Eq/min) 15 + 2 36 + 6* 21 + 4 FEK (~) 18 + 1 34 + 6* 21 + 4 PRA (ng/ml/hr) 13 + 2.0 8.3 + 1.8* 14 + 2.5 PA (ng/100 ml) 8.5 + 1.9 5.4 + 0.9* 7.0 + 1.3 . _ MAP, mean arterial pressure (blood pressure); FEH O' -~ fractional water excretion; PRA, plasma renin activity;
PA, plasma aldosterone. For definition of other abbreviations see footnote to Table II. *P<0.05 compared to control; P<0.05 compared to recovery.
The peptide produced significant decreases in plasma renin activity (PRA) and plasma aldosterone (PA), as shown in Table III. Additional studies demonstrate that this substance also inhibits the ability of angiotensin to stimulate aldosterone produc-tion by isolated adrenal cells. Thus, auriculin is potentially able to block the effects of the renin-angiotensin system at several levels including: (1) it antagonizes the direct actions of angiotensin on its target organs (blood vessels and the adrenal); and (2) it inhibits renin secretion, which leads to a reduced rate of anglotensin formation in the blood.
Based on the above data, it is evident that the synthetic and tissue derlved auriculin polypeptides :
: ~ :
zs~
possess similar activity, desirably after the synthetic auriculin polypeptide has been allowed to oxidize promoting the formation of disulfide bridges.
It is also evident from the above results that the subject compounds can be used as a potent vasorelaxant, diuretic and natriuretic in mammalian hosts.
Production of Antibody to Auriculin Compounds oE the present invention were used to provide immunoassays, particularly radioimmunoassays, for the determination of the presence or amount of auriculin in samples.
Antibody to auriculin was produced by immunizing New Zealand white rabbits subcutaneously and intramus-cularly with 250 ~g auriculin conjugated to bovine serum albumin in complete Freund's adjuvant. Rabbits were boosted at three week intervals with an identical quantity of conjugate in incomplete Freund's adjuvant.
The rabbits were bled from the ear artery 7-10 days after a boost and the resulting serum was tested for its ability to bind auriculin. Parallel control non-immune serum samples were also tested. Table IV
presents data from a representative experiment in which ~ the ability of antisera to interact specifically with `; auriculin was examined. Auriculin (500 nanogramsj was immobilized at individual wells of a polystyrene plate.
` Varying dilutions of antisera were then added to these wells and the amount of antibodies specifically bound - was quantified by adding I-labeled sheep anti-rabbit ~; IgG antisera~ This is a standard~method for determin--~ 30 ing specific antibody titres. As shown in Table IV, at a serum dilution of 1:400 significant quantities of antibody were still binding to auriculin. Specific binding was not observed with non-immune serum.
:
:
` ~ ~
-.~
:
: : ' :
' ' izsoc~s;;~-Table IV
Specific Binding of Anti-Auriculin Antisera to Immobilized Auriculin ntiserum Dilution Antibody Bound(CPM) Immune Non-Immune 1:50 6977 681 1:100 6135 685 1:200 5096 634 1:400 3898 525 ,, The experiment depicted in Table V is identical to that of Table IV, howeverr varying concentrations of non-immobilized auriculin were added concurrently with a 1:100 dilution of anti-auriculin antiserum. As shown, non-immobilized auriculin competitively dis-placed antibody binding from immobilized auriculin.
Thus, this serves as an example of a competitive displacement assay. This assay, or similar radio-immunoassays, can be used to quantlfy auriculin-like immunoreactivity in tissues or serum under a variety of physiological or pathophysiological states. Thus far, ~; the assay has been used to àetect auriculin in atrial~
extracts.~ Auriculin was not detected in ventricular extracts.
Table V
Competitive Displacement of Anti-Auriculin Binding To Immobilized Auriculin by Addition of Free Aurlculin Conc. Free Auriculin ~ Antibody Bound (nmoles) ~CPM) 0.002 63~3 :: .
~; 0.02 5603 0.2 28~3 2.0 1223 ': `'```' `: : : : ~
: ':~ : , :
:
, :, :
~ r 12SVO9~
Although the foregoing invention has been de-scribed in some detail by way of clarity and for purposes of understanding, it will be understood by those skilled in the art that modifications of the invention may be practiced while remaining within the spirit and scope of the appended claims.
`:
' :, :
:' ~: :
", .
.
-. .
85:2149-2154 (1963).
Conveniently, polypeptides may be synthesized automatically employing, for example, a Biosearch SAM
II automatic peptide synthesizer (Biosearch, Inc. San Rafael, CaliEornia) as described in the instruction manual~
Compounds of the present invention are shown to have natriuretic and diuretic activity in the intact mammal and in the kid~ey isolated from a mammal.
Furthermore, compounds of the present invention includ-ing synthetic compounds, possess vasorelaxant activity, which has been shown ~o be enhanced by slow o~idation, which indicates the li~elihood of a disulfide Cys-Cys bridge between residues 4 and 20 in the general formula ; 30 indicated previously.
Compounds oE the present invention which are shown to have the above recited physiological efects can find use in numerous therapeutical applications such as, e.g., inducing ~atriuresis, diuresis, and vasodila-tation. Thus these compounds can find use as thera-peutic agents in the treatment of various edematous * trade mark . ~
, :
:` .
~ ~s`;v~
~S~)Q9~
g states such as, for example, congestive heart failure, nephrotic syndrome and hepatic cirrhosis, in addition to hypertension and renal failure due to ineffective renal perfusion or reduced glomerular filtration rate.
These compounds can be administered to mammals for veterinary use such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents, that is in a physiologically acceptable carrier. In general the dosage will range from about OoOl to 100 ~g/kg, more usually 0.1 to 10 ~g/kg of the host body weight. Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits have been obtained.
These compounds can be administered neat, as mixtures ~ith other physiologically acceptable active or inactive materials, or with physiologically suitable carriers such as, for example, water or normal saline.
The compounds can be administered orally or paren-; terally, for example, by injection. Injection can be subcutaneous, intravenous, or by intramuscular injec-; tion.
These compounds are desirably administered in - 25 pharmaceutically effective amounts and often as pharma-~- cologically acceptable salts such as acid addition salts. Such salts can include, e.g., hydrochloride, hydrobromide, phosphate, sulphate, acetate, benzoate, malate, among others.
Compounds of the present invention can also be used for preparing antisera for use in immunoassays employing labelled reagents, usually antibodies.
Conveniently, the polypeptides can be conjugated to an antigen by means of dialdehydes, particularly from 4 to 6 carbon atoms and aliphatic, or carbodiimide. Thesè
: -. , ~s~og~ - ~
compounds and immunologic reagents may be labelled with a variety of labels such as chromophores, fluorophores such as, e.g., fluorescein or rhodamine, radioisotopes such as 125I, 35S, 14C, or 3H, or magnetized particles, by means well known in the art.
These labeled compounds and reagents, or labeled reagents capable of recognizing and specifically binding to them, can find use as, e.g., diagnostic reagents. Samples derived from biological specimens can be assayed for the presence or amount of substances having a common antigenic determinant with compounds of the present invention. In addition, monoclonal anti-bodies can be prepared by methods known in the art, which antibodies can find therapeutic use, e.g., to neutralize overproduction of immunologically related compounds ln vivo.
The following examples are provided by way of illustration, rather than implying any limitation of the subject invention.
EXPERIMENTAL
Isolation and Purification The following compound was isolated from atrial tissue as follows:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-O~
These compounds and their synthetic polypeptide analogs are referred to as auriculin.
The polypeptide was purified from an acetic acid extract of atria from 1400 male Wistar rats by first homogenizing~the ~tissue in 8 volumes of 1 N acetic acid containing 1 mM phenylmethylsulfonyl fluoride (PMSF
~; Sigma Chemical Co., St. Louis, Mo.), 3 mM ethyl-enediaminetetraacetic acid (EDTA) and 5 ~M pepstatin A
(pepsin and renin inhibitor, Sigma Chemical Co., St.
::
.
~ ' ~
:~ :
:: :
- ~2S~Q9~
--1 1~
Louis, MO). This homogenate was centrifuged at 10,800 x g for 30 minutes and the pellet was rehomogenized in 4 volumes of the original buffer. The supernate from the second extract was pooled and the pooled super-natants were neutralized with ammonium hydroxide. Theneutralized supernatants were then centrifuged at 10,000 x g for 20 minutes and lyophilized.
The lyophilized extract was subjected to gel filtration on a 2.5 X 45 cm column of Sephadex~ G-50 (fine, Pharmacia Fine Chemicals, Piscataway, NJ) which had been equilibrated with 1 N acetic-acid. The lyophilized extract was reconstituted with 6 ml buffer, centrifuged and applied to the column and then eluted at a flow rate of 0.63 ml/minute. Aliquots from each fraction were dried (Savant Speed-Vac*concentrator), reconstituted in phosphate buffered saline (PBS) and ~- assayed for natriuretic activity in intact rat and for ; vasorelaxant activity using rabbit aortic rings.
~~The results of this chromatographic step were as shown in Figure 1~, and the regions contained in horizontal bracket were lyophilized, reconstituted with 0.1% aqueous trifluoroacetic acid (TFA), pooled and centrifuged.
The pooled material was adjusted to 15% aceto-nitrile (CH3CN) and was ap~lied to a 0.39 X 30.0 centi-meter ~-Bondapak*C18 column (Waters,~Inc., Milford, MA). The material was applied using a ~aters U6K
injector and solvent delivery system (Waters, Inc., Milford, MA). Bound material was eluted at 0.1 ml/min.
with a linear gradient of solvents A (0.1~ TEA): B
(CH3CN) from 85:15 to 45:55 over 40 minutes.
Aliquots of the fractions were assayed for natri-uresis in the isolated kidney and vasorelaxant activity - as described subsequently. A broad region of coinci-dent natriuretic and vasorelaxant activi~y was eluted ` and these fractions were pooled and dried.
* trade mark b ~
~zs~9~
-12~
The material obtained and dried was reconstituted in A:B, 78:22, and rechromatographed (in 12 separate applications) at 1.0 ml/min. using a gradient of 22 tQ
34% B over 48 minutes. Aliquots of the fractions were tested for natriuretic and vasorelaxant activities as described above. The results were as displayed in Figure 1B. Fractions from the three active peaks were pooled and dried overnight.
The combined fractions from the second peak (indicated by bracketed area in Figure lB) was reconstituted in A:B, 77:23, applied to a C18 column and eluted at 0.4 ml/min. using a gradient of 23 to ~9%
B over 90 minutes. The results of this rechroma-tography were as shown in Figure 1C, where the brack-eted area indicates fractions with vasorelaxant activ-ity. Active fractions from 6 applications were pooled.
The material thus obtained was applied to a 0.39 X
30 cm ~-Bondapak CN column (Waters, Inc., Milford, MA).
The solvent system used was A (0.1% TFA in water) and B
(0.055% TFA in CH3CN). The sample was reconstituted in A:B, 90:10, and chromatographed in three separate applications at 0.6 ml/min. using a gradient of 10 to 30~ B over 60 minutes. Vasorelaxant activity was determined by the reduction in tension produced in histamine-contracted aortic rings as described subse-quently.
The active peak, indicated by the bracket in Figure 1D, was dried and sequenced. The sequence was determined from one nanomole of protein using the Applied Biosystems 470A gas-phase sequencer (Applied Biosystems Inc., Foster City, CA) in accordance with the instructions of the manufacturer. PTH amino acids were identified with a Beckman 334 T HPLC, using a 0.46 X 25 cm IBM CN-column. The gradient applied was as : :
indicated in Hunkapiller, N. W. and L. E. Hood, Methods :~ in Enzymolog~f, 91:486-492 (Academic Press, New York)~
~:
~;
:`` ::
lZS~3Q9~
(1983), with the following modiEications:the binary gradient system of Hunkapiller and Hood has been replaced by a ternary gradient system in which acetonitrile and methanol are pumped by separate pumps and the ratio of the two varied with time over the course of the gradient, with appropriate modification of the gradient program the Permaphase ETH~ guard column, specified by Hunkapiller and Hood, has been replaced with a 5 X 0.46 centimeter IBM CN analytical "mini-column"; and the analytical column is heated to - 28C whereas Hunkapillar and Hood specify 32C.
Because of the methods used to assay the products of the purification procedure, natriuretic and vaso-relaxant activity is an inherent property of the isolated and purified material.
'~' Chemical S~nthesis Compounds of the present invention having the formula:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-OH
were synthesized by solid-phase techniques. Synthesis was performed on a Biosearch SAM II automated peptide synthesi~er using t-BOC amino acids in accordance with the instructions of the manufacturer.
Following re?etitive deblocking cycles with TFA, i subse~uent couplings of amino acids were achieved with a water-soluble carbodiimide. Synthetic peptide was ~ removed from the polystyrene resins with liquid HF, `~ then was reduced, puri~ied and slowly reoxidized in accordance with the protocol of Rivier, J. E. F., J.
Amer. Chem. Soc., 96:2986-2992 (1974).
The polypeptide material was dissolved in 1 N
acetic acid containing 10 mM ~-mercaptoethanol and applied to a 2 X 96 cm column of Sephadex~ G-25 ~ * trade mark :, .~ .
. :
- :
( ~ ~250(~9~ ~
- (Pharmacia Fine Chemicals) equilabrated with the same buffer. The flow rate used was 0.335 ml/min. The major peak of UV (250 nm) absorbing material was lyophilized, resuspended in 0.05 M ammonium acetate, pH
7.2, to a final concentration of 50 ~g/ml. This material was allowed to reoxidize by exposure to air at 4DC in the dark for 60 hours and then lyophilized.
This polypeptide material was compared to par-tially-purified (Figure 1A) and purified (Figure 1D) auriculin for its ability to relax histamine-contracted aortic rings. Aortic rings were suspended in lO ml .
aerated Kreb's buffer under 1.5 grams passive tension.
The rings were precontracted with 6 X 10 M norepine-phrine, washed and allowed to return to baseline tension. A sustained contraction was induced with 5 ~M
histamine and increasing amounts of purified or synthe-tic peptide were added in cumulative fashion. The change in tension is related to the cumulative amount of protein added, as shown in Figure 2, wherein the open triangles represent polypeptide purified by gel filtration only, closed triangles represent completely purified polypeptide, open circles represent synthetic peptide before oxidation an8 closed circles represent synthetic polypeptide after oxidation.
Biologic Activity The biologic;activities of auriculin and its chemically synthesized analog were determined and compared using intact rats, isolated rat kidneys, intact dogs and isolated rabbit thoracic aortic rings.
The synthetic auriculin analog was compared to partially purified (gel filtration step) and purified (HPLC) auriculin for its ability to relax histamine-contracted aortic rings. Rings were suspended in 10 ml aerated Kreb's buffer under 1.5 g passive tension. ~
:' :
: ~
,, ~ -:-- , ~-; : ' , ' ' ~:
--:~25~()9;~
Rings were precontracted with 6 X 10 M norepine-phrine, washed and allowed to return to baseline tension, as described (Kleinert, H. D. (1984), supra).
A sustained contraction was induced with 5 uM histamine and then increasing amounts of purified auriculin or synthetic polypeptide were then added in cumulative fashion. The change in tension was shown to be related to the cumulative amount of protein added, as seen in Figure 2.
As alternatives, angiotensin, norepinephrine and potassium-induced depolarization were-used instead of histamine. Purified and synthetic auriculin demon-strated similar vasorelaxant effects.
The synthetic polypeptide auriculin analog was also found to be natriuretic in the intact rat. Syn-thetic peptide was administered as a bolus injection to Inactin anesthetized rats (100 mg/kg, average weight 399 g) which were maintained on a constant infusion of normal saline at 2.2 ml/hr. The results were as shown in Table I, wherein the change in each parameter was assessed by the difference between the averaqe of three control periods (10 mins. each) and the ~irst experi-mental period (maximum response). Data are expressed as mean + SE.
'~ ~ - ; :~
:
:: : : ~ '~ ' .
( ' (~',,, ~l2SVO9~
Table I
Natriuretic Effect of Synthetic Auriculin in Intact Rats Dose V UNaV UKV
5(~g/kg) (~l/min? (~Eq/min)(~Eq/min) 1.2 (n=4)25.5 + 9.7 2.5 + 1.11.6 + 0.2 2.6 ~n=4)41.3 + 19.5 6.7 + 4.14.4 + 1.4 5.0 (n=4)52.8 + 6.5 9.1 + 1.03,7 + 0.5 7.2 (n=3)112.0 + 12.818.3 + 0.53.1 + 0.8 . _ _ .. _ _ ... .. .
- 10 V, urine flow rate; UNaV, urinary so~ium excretion rate; UI~V, urinary potassiwn excretion rate. Control values for the 15 animals were: V, 10.3 + 2.9 ~l/min;
UNaV, 0.93 + 0.5 ~Eq/min; and UKV, 1.6 ~ 0.4 ~Eq/min.
The natriuretic activity of the synthetic polypep-tide auriculin analog was also measured in isolated rat ~; kidney. Functioning isolated rat kidneys were perfused in a closed-circuit system, as described in Camargo, M.J.F. et al. Am.J.Physiol., In Press. (19843. After control clearance periods, 150 ng of syntheti~ peptide was added to the perfusate. The ef~ects on each parameter were noted immediately and reached a maximum during the fourth 10 minute clearance period. These peak vaIues are expressed in,Table II as the experi-mental data. ~
.: :
;
: ' :
..
: ~ -~ZSOO9;~
Table II
Effects of Synthetic Auriculin on Renal Function in the Isolated Perfused Rat Kidney Control Experimental GFR (ml/min) 0.43 + 0.05 0.63 + 0.03*
FF 0.014 + 0.002 0.021 + 0.001*
RVR (mmHg/ml min) 2.9 + 0.1 3.9 + 0O3*
V (~l/min) 19.8 ~ 4.8 97.6 + 19.4*
FLNa (~Eq/min) 60.2 + 7.9 90.1 + 5.2*
TNa (~Eq/min) 60.0 + 7.6 84.2 + 4.8*
UNaV (~Eq/min) 0.66 + 0.35 6.01 + 1.99*
Na ( ) 0~97 + 0.38 6.6 ~ 2.0*
UKV (~Eq/min) 0.44 + 0.19 1.46 ~ 0.16*
FEK (~) 19.8 + 5.3 52.1 + 6.2*
_ GFR, glomerular filtration rate; FF, filtration frac-tion; RVR, renal vascular resistance; V, urine flow rate; FLNa, filtered load of sodium; TNa, tubular reabsorption of sodium; UNaV, urinary sodium excretion rate; FEN ~ fractional sodium excretion; UKV, urinary potassium excretion rate; FEK, fractional potassium excretion~ Results are the mean + SE of 4 kidneys.
*P 0.05 compared to control (Student's t test).
In these results it can be seen that isolated kidneys perfused in the absence of vasoconstrictors, the synthetic poIypeptide increased renal vascular resistance (see also Figure 3A), filtration fraction and glomerular filtration rate. In contrast, in isolated kidney pre-contracted with endogenously generated angiotensin, the synthetic peptide decreased vascular resistance (see Fiqure 3B). These effects with the synthetic peptide show that auriculin can have both renal vasoconstrictive and vasorelaxant activity depending on the absence or presence of endogenous vasoconstrictors. The natriuresis observed in the ~,.`,,, - :
.
(~ ,? (', ~2SOQ9;~
isolated kidney can result from a renal vasocon-strictive effect preferentially expressed in the efferent arteriole.
Renal and hemodynamic effects have also been measured in anesthetized dogs receiving a constant infusion of the synthetic peptide (1 ~g/kg bolus, followed by 0.1 ~g/kg/min for 1 hour). Immediate effects were noted on blood pressure, GFR and urine flow rate and electrolyte excretion which were sus-tained throughout the infusion. The "experimental"data presented for these parameters in Table III are the average values obtained during the infusion. Mean arterial pressure (MAP) fell consistently by l0-15~
while GFR rose by 25-35%, in association with a sus-tained diuresis and natriuresis (Table III). All theseparameters returned to control (i.e. pre-infusion) levels during the recovery period (i.e. following termination of the infusion).
::: :
:: :
: ~ ' ' .
J~2S(~9~
--, g Table III
-Hemodynamic, Renal and Metabolic Effects Of Synthetic Auriculin in Anesthetized Dogs Control Experimental_ Recovery MAP (mm Hg) 134 + 5 122 ~ 4* 136 + 4 GFR (ml/min) 25.5 + 2.7 32.3 + 4.1* 25.4 + 3.3 V (ml/min) 0.21 + 0.03 1.06 + 0.14* 0.37 + 0.05 2 0.9 + 0.2 3.4 + 0.3* 1.5 + 0.2 UNaV ( Eq/min) 38 + 6 187 + 35* 68 + 14 FENa (~) 1.1 + 0.2 4.1 + 0.5* 1.9 0.4 UKV ( Eq/min) 15 + 2 36 + 6* 21 + 4 FEK (~) 18 + 1 34 + 6* 21 + 4 PRA (ng/ml/hr) 13 + 2.0 8.3 + 1.8* 14 + 2.5 PA (ng/100 ml) 8.5 + 1.9 5.4 + 0.9* 7.0 + 1.3 . _ MAP, mean arterial pressure (blood pressure); FEH O' -~ fractional water excretion; PRA, plasma renin activity;
PA, plasma aldosterone. For definition of other abbreviations see footnote to Table II. *P<0.05 compared to control; P<0.05 compared to recovery.
The peptide produced significant decreases in plasma renin activity (PRA) and plasma aldosterone (PA), as shown in Table III. Additional studies demonstrate that this substance also inhibits the ability of angiotensin to stimulate aldosterone produc-tion by isolated adrenal cells. Thus, auriculin is potentially able to block the effects of the renin-angiotensin system at several levels including: (1) it antagonizes the direct actions of angiotensin on its target organs (blood vessels and the adrenal); and (2) it inhibits renin secretion, which leads to a reduced rate of anglotensin formation in the blood.
Based on the above data, it is evident that the synthetic and tissue derlved auriculin polypeptides :
: ~ :
zs~
possess similar activity, desirably after the synthetic auriculin polypeptide has been allowed to oxidize promoting the formation of disulfide bridges.
It is also evident from the above results that the subject compounds can be used as a potent vasorelaxant, diuretic and natriuretic in mammalian hosts.
Production of Antibody to Auriculin Compounds oE the present invention were used to provide immunoassays, particularly radioimmunoassays, for the determination of the presence or amount of auriculin in samples.
Antibody to auriculin was produced by immunizing New Zealand white rabbits subcutaneously and intramus-cularly with 250 ~g auriculin conjugated to bovine serum albumin in complete Freund's adjuvant. Rabbits were boosted at three week intervals with an identical quantity of conjugate in incomplete Freund's adjuvant.
The rabbits were bled from the ear artery 7-10 days after a boost and the resulting serum was tested for its ability to bind auriculin. Parallel control non-immune serum samples were also tested. Table IV
presents data from a representative experiment in which ~ the ability of antisera to interact specifically with `; auriculin was examined. Auriculin (500 nanogramsj was immobilized at individual wells of a polystyrene plate.
` Varying dilutions of antisera were then added to these wells and the amount of antibodies specifically bound - was quantified by adding I-labeled sheep anti-rabbit ~; IgG antisera~ This is a standard~method for determin--~ 30 ing specific antibody titres. As shown in Table IV, at a serum dilution of 1:400 significant quantities of antibody were still binding to auriculin. Specific binding was not observed with non-immune serum.
:
:
` ~ ~
-.~
:
: : ' :
' ' izsoc~s;;~-Table IV
Specific Binding of Anti-Auriculin Antisera to Immobilized Auriculin ntiserum Dilution Antibody Bound(CPM) Immune Non-Immune 1:50 6977 681 1:100 6135 685 1:200 5096 634 1:400 3898 525 ,, The experiment depicted in Table V is identical to that of Table IV, howeverr varying concentrations of non-immobilized auriculin were added concurrently with a 1:100 dilution of anti-auriculin antiserum. As shown, non-immobilized auriculin competitively dis-placed antibody binding from immobilized auriculin.
Thus, this serves as an example of a competitive displacement assay. This assay, or similar radio-immunoassays, can be used to quantlfy auriculin-like immunoreactivity in tissues or serum under a variety of physiological or pathophysiological states. Thus far, ~; the assay has been used to àetect auriculin in atrial~
extracts.~ Auriculin was not detected in ventricular extracts.
Table V
Competitive Displacement of Anti-Auriculin Binding To Immobilized Auriculin by Addition of Free Aurlculin Conc. Free Auriculin ~ Antibody Bound (nmoles) ~CPM) 0.002 63~3 :: .
~; 0.02 5603 0.2 28~3 2.0 1223 ': `'```' `: : : : ~
: ':~ : , :
:
, :, :
~ r 12SVO9~
Although the foregoing invention has been de-scribed in some detail by way of clarity and for purposes of understanding, it will be understood by those skilled in the art that modifications of the invention may be practiced while remaining within the spirit and scope of the appended claims.
`:
' :, :
:' ~: :
", .
.
-. .
Claims (3)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A polypeptide useful as a natriuretic, diuretic and antagonist of vasoconstrictors including angiotensin in mammals, said polypeptide comprising the formula:
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH.
H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X
where X is OH or Tyr-OH.
2. A pharmaceutical composition useful as a natriuretic, diuretic and vasorelaxant in mammals, comprising a polypeptide compound in accordance with claim 1 in a thera-peutically effective amount, together with a physiologically suitable carrier.
3. A composition comprising antibodies which are capable of recognizing and specifically binding to immuno-reactive polypeptides comprising the polypeptides of claim 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US602,117 | 1984-04-19 | ||
US06/602,117 US4618600A (en) | 1984-04-19 | 1984-04-19 | Novel polypeptide diuretic/vasodilators |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1250092A true CA1250092A (en) | 1989-02-14 |
Family
ID=24410038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000479612A Expired CA1250092A (en) | 1984-04-19 | 1985-04-19 | Polypeptide diuretic/vasodilators |
Country Status (3)
Country | Link |
---|---|
US (2) | US4618600A (en) |
CA (1) | CA1250092A (en) |
ZA (1) | ZA852962B (en) |
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212286A (en) * | 1984-04-19 | 1993-05-18 | Scios Nova Inc. | Atrial natriuretic/vasodilator peptide compounds |
US4894437A (en) * | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US5057603A (en) * | 1986-01-31 | 1991-10-15 | Merck & Co., Inc. | Peptides having ANF activity |
US4804650A (en) * | 1986-10-28 | 1989-02-14 | Biotechnology Research Associates, J.V. | Analogs of atrial natriuretic peptides |
US4743585A (en) * | 1986-11-21 | 1988-05-10 | Warner-Lambert Company | Renin inhibitors |
US4816443A (en) * | 1987-05-19 | 1989-03-28 | Merck & Co., Inc. | Piptides having ANF activity |
EP0310887B1 (en) * | 1987-10-09 | 1993-06-02 | Takeda Chemical Industries, Ltd. | Vasoconstrictor peptide |
CA1337891C (en) * | 1987-12-16 | 1996-01-02 | John Dimaio | Anf derivatives with novel bridging |
NZ229098A (en) * | 1988-05-13 | 1992-10-28 | Amgen Inc | (bg-csf) bovine granulocyte colony stimulating factor, recombinant methods and pharmaceuticals |
US5114923A (en) * | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
CA1339210C (en) * | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
US5328899A (en) * | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
WO1990014845A1 (en) * | 1989-06-09 | 1990-12-13 | Institut De Recherches Cliniques De Montreal | Nuclear imaging uses of radio-labelled atrial natriuretic factor |
US5182261A (en) * | 1989-07-13 | 1993-01-26 | The Rockefeller University | Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof |
US5260210A (en) * | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
US6033665A (en) * | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
US5202239A (en) * | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
DK0604552T3 (en) * | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Process for the synthesis of different assemblies of oligomers |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
US5674977A (en) * | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) * | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5656454A (en) * | 1994-10-04 | 1997-08-12 | President And Fellows Of Harvard College | Endothelial cell-specific enhancer |
US5767578A (en) * | 1994-10-12 | 1998-06-16 | Siliconix Incorporated | Surface mount and flip chip technology with diamond film passivation for total integated circuit isolation |
NO319913B1 (en) * | 1994-12-09 | 2005-10-03 | Shionogi & Co | Procedure for sandwich immunoassay for N-peptide |
US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US5965533A (en) | 1997-05-23 | 1999-10-12 | Baxter International Inc. | Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20110207758A1 (en) | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
US20070129761A1 (en) * | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
WO2006063132A2 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
US20070021803A1 (en) | 2005-07-22 | 2007-01-25 | The Foundry Inc. | Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction |
WO2007115175A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
AU2007233123A1 (en) * | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
EP2465574B1 (en) | 2006-06-28 | 2015-10-28 | Ardian, Inc. | Systems for thermally-induced renal neuromodulation |
US8436140B2 (en) * | 2008-06-02 | 2013-05-07 | Washington University | Natriuretic peptide-mediated imaging of atherosclerotic plaque |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8808345B2 (en) | 2008-12-31 | 2014-08-19 | Medtronic Ardian Luxembourg S.A.R.L. | Handle assemblies for intravascular treatment devices and associated systems and methods |
US20110208175A1 (en) * | 2010-02-24 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Treating Sleep Apnea Via Renal Denervation |
US8556891B2 (en) | 2010-03-03 | 2013-10-15 | Medtronic Ablation Frontiers Llc | Variable-output radiofrequency ablation power supply |
US8870863B2 (en) | 2010-04-26 | 2014-10-28 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
CN103547229B (en) | 2010-08-05 | 2017-09-26 | 美敦力Af卢森堡有限责任公司 | Cryogenic ablation device, the system and method modulated for renal nerve |
US9084610B2 (en) | 2010-10-21 | 2015-07-21 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses, systems, and methods for renal neuromodulation |
TW201221174A (en) | 2010-10-25 | 2012-06-01 | Medtronic Ardian Luxembourg | Microwave catheter apparatuses, systems, and methods for renal neuromodulation |
EP3100696B1 (en) | 2010-10-25 | 2023-01-11 | Medtronic Ardian Luxembourg S.à.r.l. | Catheter apparatuses having multi-electrode arrays for renal neuromodulation |
JP6046041B2 (en) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | Devices, systems, and methods for neuromodulation therapy evaluation and feedback |
US9060755B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US10292754B2 (en) | 2010-11-17 | 2019-05-21 | Medtronic Ardian Luxembourg S.A.R.L. | Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods |
EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
CA2832311A1 (en) | 2011-04-08 | 2012-11-29 | Covidien Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
CN103930061B (en) | 2011-04-25 | 2016-09-14 | 美敦力阿迪安卢森堡有限责任公司 | Relevant low temperature sacculus for restricted conduit wall cryogenic ablation limits the device and method disposed |
EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | Chimeric natriuretic peptide compositions and methods of preparation |
CN104125799A (en) | 2011-11-07 | 2014-10-29 | 美敦力阿迪安卢森堡有限责任公司 | Endovascular nerve monitoring devices and associated systems and methods |
US9192766B2 (en) | 2011-12-02 | 2015-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and devices for treatment of polycystic kidney disease |
AU2013230883A1 (en) | 2012-03-07 | 2014-09-11 | Medtronic Af Luxembourg S.A.R.L. | Selective modulation of renal nerves |
AU2013230774B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Gastrointestinal neuromodulation and associated systems and methods |
AU2013230906A1 (en) | 2012-03-08 | 2014-09-18 | Medtronic Af Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of sexual dysfunction |
CA2865242A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems and methods |
WO2013134472A1 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Renal neuromodulation methods and systems for treatment of hyperaldosteronism |
US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
AU2013230893B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the management of pain |
US9943354B2 (en) | 2012-04-27 | 2018-04-17 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for localized inhibition of inflammation by ablation |
US9241752B2 (en) | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
WO2013162700A1 (en) | 2012-04-27 | 2013-10-31 | Medtronic Ardian Luxembourg Sarl | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
US9848950B2 (en) | 2012-04-27 | 2017-12-26 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and devices for localized disease treatment by ablation |
US10258791B2 (en) | 2012-04-27 | 2019-04-16 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies for neuromodulation proximate a bifurcation of a renal artery and associated systems and methods |
CA2872189A1 (en) | 2012-05-11 | 2013-11-14 | William W. CHANG | Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods |
US8951296B2 (en) | 2012-06-29 | 2015-02-10 | Medtronic Ardian Luxembourg S.A.R.L. | Devices and methods for photodynamically modulating neural function in a human |
US8612022B1 (en) | 2012-09-13 | 2013-12-17 | Invatec S.P.A. | Neuromodulation catheters and associated systems and methods |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
CN104968287B (en) | 2012-10-22 | 2018-05-22 | 美敦力Af卢森堡有限责任公司 | Flexible conduit with improvement |
US9044575B2 (en) | 2012-10-22 | 2015-06-02 | Medtronic Adrian Luxembourg S.a.r.l. | Catheters with enhanced flexibility and associated devices, systems, and methods |
US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
US9066726B2 (en) | 2013-03-15 | 2015-06-30 | Medtronic Ardian Luxembourg S.A.R.L. | Multi-electrode apposition judgment using pressure elements |
EP2968919B1 (en) | 2013-03-15 | 2021-08-25 | Medtronic Ardian Luxembourg S.à.r.l. | Controlled neuromodulation systems |
US9179974B2 (en) | 2013-03-15 | 2015-11-10 | Medtronic Ardian Luxembourg S.A.R.L. | Helical push wire electrode |
EP2996754B1 (en) | 2013-05-18 | 2023-04-26 | Medtronic Ardian Luxembourg S.à.r.l. | Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices and systems |
US9339332B2 (en) | 2013-08-30 | 2016-05-17 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters with nerve monitoring features for transmitting digital neural signals and associated systems and methods |
US9326816B2 (en) | 2013-08-30 | 2016-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation systems having nerve monitoring assemblies and associated devices, systems, and methods |
US20150073515A1 (en) | 2013-09-09 | 2015-03-12 | Medtronic Ardian Luxembourg S.a.r.I. | Neuromodulation Catheter Devices and Systems Having Energy Delivering Thermocouple Assemblies and Associated Methods |
US9138578B2 (en) | 2013-09-10 | 2015-09-22 | Medtronic Ardian Luxembourg S.A.R.L. | Endovascular catheters with tuned control members and associated systems and methods |
US10433902B2 (en) | 2013-10-23 | 2019-10-08 | Medtronic Ardian Luxembourg S.A.R.L. | Current control methods and systems |
EP3099377B1 (en) | 2014-01-27 | 2022-03-02 | Medtronic Ireland Manufacturing Unlimited Company | Neuromodulation catheters having jacketed neuromodulation elements and related devices |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
US10463424B2 (en) | 2014-03-11 | 2019-11-05 | Medtronic Ardian Luxembourg S.A.R.L. | Catheters with independent radial-expansion members and associated devices, systems, and methods |
US9579149B2 (en) | 2014-03-13 | 2017-02-28 | Medtronic Ardian Luxembourg S.A.R.L. | Low profile catheter assemblies and associated systems and methods |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
WO2015164280A1 (en) | 2014-04-24 | 2015-10-29 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation catheters having braided shafts and associated systems and methods |
US10610292B2 (en) | 2014-04-25 | 2020-04-07 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, systems, and methods for monitoring and/or controlling deployment of a neuromodulation element within a body lumen and related technology |
US10709490B2 (en) | 2014-05-07 | 2020-07-14 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter assemblies comprising a direct heating element for renal neuromodulation and associated systems and methods |
WO2016033543A1 (en) | 2014-08-28 | 2016-03-03 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for assessing efficacy of renal neuromodulation and associated systems and devices |
US10368775B2 (en) | 2014-10-01 | 2019-08-06 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for evaluating neuromodulation therapy via hemodynamic responses |
EP3943032A1 (en) | 2014-11-14 | 2022-01-26 | Medtronic Ardian Luxembourg S.à.r.l. | Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems |
US10667736B2 (en) | 2014-12-17 | 2020-06-02 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing sympathetic nervous system tone for neuromodulation therapy |
US10736692B2 (en) | 2016-04-28 | 2020-08-11 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation and associated systems and methods for the treatment of cancer |
US10231784B2 (en) | 2016-10-28 | 2019-03-19 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics |
US10646713B2 (en) | 2017-02-22 | 2020-05-12 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and associated methods for treating patients via renal neuromodulation to reduce a risk of developing cognitive impairment |
US11160982B2 (en) | 2017-07-05 | 2021-11-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating post-traumatic stress disorder in patients via renal neuromodulation |
US10945788B2 (en) | 2017-07-05 | 2021-03-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating depression in patients via renal neuromodulation |
US11284934B2 (en) | 2017-07-05 | 2022-03-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for treating sleep disorders in patients via renal neuromodulation |
EP3709919A1 (en) | 2017-11-17 | 2020-09-23 | Medtronic Ardian Luxembourg S.à.r.l. | Systems, devices, and associated methods for neuromodulation with enhanced nerve targeting |
US10959669B2 (en) | 2018-01-24 | 2021-03-30 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing the efficacy of neuromodulation therapy |
US11253189B2 (en) | 2018-01-24 | 2022-02-22 | Medtronic Ardian Luxembourg S.A.R.L. | Systems, devices, and methods for evaluating neuromodulation therapy via detection of magnetic fields |
US11478298B2 (en) | 2018-01-24 | 2022-10-25 | Medtronic Ardian Luxembourg S.A.R.L. | Controlled irrigation for neuromodulation systems and associated methods |
US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
US11633120B2 (en) | 2018-09-04 | 2023-04-25 | Medtronic Ardian Luxembourg S.A.R.L. | Systems and methods for assessing efficacy of renal neuromodulation therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016258A (en) * | 1975-08-05 | 1977-04-05 | Said Sami I | Vasoactive intestinal peptide from fowl |
US4113711A (en) * | 1976-01-19 | 1978-09-12 | Said Sami I | Vasoactive lung polypeptides |
US4237046A (en) * | 1979-04-27 | 1980-12-02 | Miklos Bodanszky | Polypeptides and methods of preparation |
EP0116784B1 (en) * | 1982-02-22 | 1992-06-10 | Queen's University At Kingston | Atrial natriuretic factor |
AU572173B2 (en) * | 1983-08-29 | 1988-05-05 | Institut De Recherches Cliniques De Montreal | Natriuretic factors |
US4496544A (en) * | 1983-11-10 | 1985-01-29 | Washington University | Atrial Peptides |
US4508712A (en) * | 1984-01-10 | 1985-04-02 | Washington University | Atrial peptide |
US4557864A (en) * | 1984-01-10 | 1985-12-10 | Washington University | Atrial peptides |
-
1984
- 1984-04-19 US US06/602,117 patent/US4618600A/en not_active Expired - Lifetime
-
1985
- 1985-04-16 US US06/766,030 patent/US4764504A/en not_active Expired - Lifetime
- 1985-04-19 ZA ZA852962A patent/ZA852962B/en unknown
- 1985-04-19 CA CA000479612A patent/CA1250092A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
US4618600A (en) | 1986-10-21 |
ZA852962B (en) | 1986-02-26 |
US4764504A (en) | 1988-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1250092A (en) | Polypeptide diuretic/vasodilators | |
US5830703A (en) | DNA encoding adrenomedullin | |
US4935492A (en) | Cyclic analogs of atrial natriuretic peptides | |
Schwartz et al. | Ser-Leu-Arg-Arg-atriopeptin III: the major circulating form of atrial peptide | |
Kitamura et al. | Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma | |
Atlas et al. | Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide | |
US5212286A (en) | Atrial natriuretic/vasodilator peptide compounds | |
Kitamura et al. | The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma | |
Washimine et al. | Immunoreactive proadrenomedullin N-terminal 20 peptide in human tissue, plasma and urine | |
US5449662A (en) | Atrial natriuretic peptide clearance inhibitors which resist degradation | |
US4609725A (en) | Cardiac atrial peptides | |
US5936064A (en) | Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex | |
US4804650A (en) | Analogs of atrial natriuretic peptides | |
KR940001711B1 (en) | Analogs of atrial natriuretic peptides | |
US5449766A (en) | DNA encoding NEI and NGE peptides | |
JPH0474198A (en) | Swine derived new physiologically active peptide (cnp-53) | |
US5047397A (en) | Linear analogs of atrial natriuretic peptides | |
Yoshimi et al. | Radioimmunoassay for β-endorphin: presence of immunoreactive “big-big” β-endorphin (“big” β-lipotropin) in human and rat pituitaries | |
Kitamura et al. | Isolation and characterization of peptides which act on rat platelets, from a pheochromocytoma | |
US5258368A (en) | Atrial natriuretic/vasodilator peptide compounds | |
DE3742997A1 (en) | PEPTIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE FOR THE OBTAINING OF ANTIBODIES, AND THEIR USE FOR BLOCKING THE PAI-1 ACTIVITY OF HUMAN BLOOD | |
Arai et al. | Characterization of immunoreactive endothelin in human urine | |
JP3042782B2 (en) | Atrial natriuretic peptide-enhancing compound | |
CA1339388C (en) | Atrial hypotensive peptide having 46 amino acids | |
CA1340317C (en) | Atrial natriuretic factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |